Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) announced two upcoming oral presentations at the International Society for Respiratory Viruses (ISRV) conference in Singapore, September 17-20, 2025. The presentations will feature clinical and preclinical data for their drug candidate CD388.
The first presentation is a late-breaking abstract showcasing Phase 2b clinical trial results (NAVIGATE study) evaluating CD388's efficacy and safety for influenza prevention in healthy adults. The second presentation will discuss preclinical data demonstrating CD388's protective effects against H5N1 influenza virus in ferret models.
Positive
- None.
Negative
- None.
News Market Reaction – CDTX
On the day this news was published, CDTX declined 0.56%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore.
Presentation details are summarized below:
Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy Adults
Presenter: Rick Bright, Ph.D. Bright Global Health, Cidara Therapeutics
Session: AVG Session 3
Session Date and Time: Wednesday, September 17, 2025, 3:50 – 4:05 p.m. SGT
Abstract Title: A Single Prophylactic dose of CD388 Provides Protection Against Highly Pathogenic Bovine-Origin Influenza A (H5N1) Virus in the Ferret Model
Presenter: Andreev Konstantin, Ph.D. St. Jude Children’s Research Hospital
Session: Parallel Session 2 (Track 1)
Session Date and Time: Friday, September 19, 2025, 10:30 a.m. – 12:30 p.m. SGT
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com
